Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Botanix Pharmaceuticals Ltd

Healthcare AU BOT

0.022AUD
0.001(4.76%)

Last update at 2026-06-03T06:10:00Z

Day Range

0.020.02
LowHigh

52 Week Range

0.020.36
LowHigh

Fundamentals

  • Previous Close 0.02
  • Market Cap62.57M
  • Volume13375905
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-82.22973M
  • Revenue TTM21.92M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 13.39M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -86.39619M -13.87000M -9.15397M -13.17075M -3.33400M
Minority interest - - - - -
Net income -86.39619M -13.87000M -9.15397M -13.17075M -10.27537M
Selling general administrative 9.09M 6.65M 3.04M 3.56M 2.24M
Selling and marketing expenses 38.46M 0.33M - - -
Gross profit 2.02M -6.11880M -5.62456M 0.10M -
Reconciled depreciation 2.26M 0.07M 0.11M 0.14M 0.09M
Ebit -82.91479M -15.32672M -9.07224M -13.13331M -3.27806M
Ebitda -80.65093M -15.25411M -8.96180M -12.98981M -3.18384M
Depreciation and amortization 2.26M 0.07M 0.11M 0.14M 0.09M
Non operating income net other - - - - -
Operating income -80.79488M -15.73231M -9.12634M -13.13331M -3.27806M
Other operating expenses 86.58M 16.06M -1.45557M 15.94M 10.27M
Interest expense 5.37M 0.01M 0.08M 0.04M 0.06M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.88M 0.08M 0.09M 0.04M 0.06M
Net interest income -0.09380M 0.07M -0.01578M -0.00007M 0.05M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.46767M 3.74M 2.81M 6.94M
Total revenue 5.79M 0.60M 0.10M 0.10M 0.10M
Total operating expenses 82.81M 9.34M 12.90M 15.94M 10.27M
Cost of revenue 3.77M 7.15M 5.73M - -
Total other income expense net -5.60130M 1.86M 3.66M 2.77M -0.05594M
Discontinued operations - - - - -
Net income from continuing ops -86.39619M -13.86971M -9.15397M -13.17075M -3.33400M
Net income applicable to common shares -86.39619M -13.86971M -9.15397M -13.17075M -3.33400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 129.10M 112.46M 24.84M 14.04M 21.95M
Intangible assets 28.12M - 10.73M 3.30M 3.30M
Earning assets - - - - -
Other current assets - 1.57M 0.09M 0.03M 0.00992M
Total liab 47.80M 3.73M 1.88M 5.89M 1.15M
Total stockholder equity 81.30M 108.73M 22.95M 8.15M 20.80M
Deferred long term liab - - 3.87M - -
Other current liab - 1.00M 0.49M 1.20M 0.39M
Common stock - 188.32M 93.49M 71.48M 71.48M
Capital stock 226.30M - 93.49M 71.48M 71.48M
Retained earnings -177.18783M -90.79164M -76.92193M -67.76796M -54.59721M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M 3.94M 0.06M 0.06M
Cash 64.97M 79.31M 10.25M 7.29M 21.55M
Cash and equivalents - - - - -
Total current liabilities 24.92M 3.73M 1.88M 5.89M 1.04M
Current deferred revenue - - - -1.10828M -0.14714M
Net debt - -79.30813M -10.25039M -7.16324M -21.29559M
Short term debt - - 0.00000M 0.12M 0.15M
Short long term debt 8.82M - - - -
Short long term debt total - - - 0.12M 0.26M
Other stockholder equity - - -16.56773M -3.70781M -16.87855M
Property plant equipment - - 0.07M 0.18M 0.28M
Total current assets 99.59M 82.90M 13.98M 10.50M 21.61M
Long term investments - - - 0.06M 0.06M
Net tangible assets - - 16.10M 4.86M 20.80M
Short term investments - - - - -
Net receivables 2.85M 0.82M 0.49M 0.14M 0.05M
Long term debt 22.07M - - - -
Inventory 28.08M 1.21M 3.15M 3.04M 3.04M
Accounts payable 8.87M 2.73M 1.39M 5.67M 0.65M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 11.20M 6.38M 4.44M 3.92M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 29.49M 0.06M 0.06M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 29.51M 29.56M 10.86M 3.54M 0.34M
Capital lease obligations 1.22M - - 0.12M 0.26M
Long term debt total - - 0.00000M 0.00000M 0.11M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -1.04989M -17.99947M -7.05372M -2.92187M -0.00828M
Change to liabilities - - -4.03868M 4.65M -0.38174M
Total cashflows from investing activities -1.04989M -17.99947M -7.05372M -2.92187M -0.00828M
Net borrowings 27.63M - -0.12241M -0.15241M -0.12550M
Total cash from financing activities 65.36M 95.10M 22.03M -0.15241M -0.12550M
Change to operating activities - - - - -
Net income -86.39619M -13.86971M -9.15397M -13.17075M -3.33400M
Change in cash -14.34155M 69.06M 2.96M -14.26925M -3.09028M
Begin period cash flow 79.31M 10.25M 7.29M 21.55M 24.65M
End period cash flow 64.97M 79.31M 10.25M 7.29M 21.55M
Total cash from operating activities -78.58474M -8.12728M -12.07406M -11.18406M -2.96802M
Issuance of capital stock 40.46M 100.85M 23.59M - -
Depreciation 7.37M 0.07M 0.11M 0.14M 0.09M
Other cashflows from investing activities -0.76346M -17.88677M - - 0.00000M
Dividends paid - - -1.84924M 20.30M -
Change to inventory -26.86626M 1.68M -0.10268M -3.04435M -3.04435M
Change to account receivables -4.16055M -2.34427M -0.40999M -0.09680M 0.09M
Sale purchase of stock -2.53868M -5.75664M -1.43836M -1.43836M 0.00000M
Other cashflows from financing activities 27.63M -17.99947M 3.58M -0.15241M -0.12550M
Change to netincome - - 1.52M 1.84M 0.57M
Capital expenditures 0.29M 18.00M 7.05M 2.92M 0.00828M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -31.02681M 1.28M -0.51267M -3.14114M 0.09M
Stock based compensation 20.52M 4.39M 1.52M 0.33M 0.57M
Other non cash items 10.95M -0.00002M -3.03052M 1.84M 0.27M
Free cash flow -78.87117M -26.12675M -19.12778M -14.10592M -2.97630M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BOT
Botanix Pharmaceuticals Ltd		 0.001 4.76% 0.02 - 5.84 2.85 1.21 2.91 -11.0772
CSL
CSL Ltd		 -0.32 0.35% 92.24 11.33 14.35 3.03 1.83 2.86 8.58
TLX
TELIX Pharmaceuticals Ltd		 -0.43 3.40% 12.20 - 2500.00 5.49 7.94 4.51 103.05
MSB
Mesoblast Ltd		 -0.03 1.46% 2.02 - 454.55 40.14 3.31 30.21 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.17 1.24% 13.59 60.00 55.25 27.00 5.17 22.51 66.05

Reports Covered

Stock Research & News

View All

Profile

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in Melbourne, Australia.

Botanix Pharmaceuticals Ltd

Tower 5, Collins Square, Melbourne, WA, Australia, 3008

Key Executives

Name Title Year Born
Mr. Vincent P. Ippolito MD & Exec. Chairman 1959
Dr. Howie McKibbon Chief Operating Officer NA
Dr. Henry William Bosch BA, Ph.D. Chief Scientific Officer & Exec. Director NA
Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB Exec. Director 1973
Dr. Clarence L. Young M.D. Chief Medical Officer 1956
Ms. Lynda Berne Head of Commercial NA
Dr. Jack Hoblitzell Ph.D. Sr. VP of Pharmaceutical Devel. NA
Dr. Patricia S. Walker M.D., Ph.D. Chief Medical Adviser 1959
Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA Company Sec. NA
Mr. Vincent P. Ippolito MD & Executive Chairman 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.